Introduction
============

Hereditary multiple osteochondroma (HMO), also known as hereditary multiple exostoses, is characterized by multiple exogenous exostoses in the skeletal system ([@b1-ol-0-0-7838],[@b2-ol-0-0-7838]). The incidence of HMO in Europe is \~1:100,000 ([@b3-ol-0-0-7838]), and in the United States is \~1:50,000 ([@b4-ol-0-0-7838]); however, to the best of our knowledge, its incidence in China is presently unknown. It occurs more frequently in males than in females (\~1.5:1). Symptoms in females are not serious and the disease is often not diagnosed ([@b5-ol-0-0-7838],[@b6-ol-0-0-7838]). HMO is autosomal dominant ([@b7-ol-0-0-7838]) and has an penetrance of 100% ([@b3-ol-0-0-7838],[@b4-ol-0-0-7838]). Approximately 70% of patients with HMO have a family history of the disorder ([@b5-ol-0-0-7838],[@b8-ol-0-0-7838],[@b9-ol-0-0-7838]). The disease affects regions of the humerus (10--50%), forearm (39--60%), knee (33%), ankle (25%), and other long bones; the scapula and ribs are affected, and the majority of osteochondroma is distributed symmetrically ([@b4-ol-0-0-7838],[@b10-ol-0-0-7838]--[@b12-ol-0-0-7838]).

Studies concerning the etiology and molecular genetic background of HMO have indicated that the majority cases are associated with mutations in the exostosin (*EXT*) tumor inhibition genes ([@b13-ol-0-0-7838]); specifically, *EXT1, EXT2*, and *EXT3*, which are located at 11p11-13, 8c23-24.1, and on chromosome 19p, respectively, are associated with HMO ([@b14-ol-0-0-7838],[@b15-ol-0-0-7838]). *EXT* encodes a type II transmembrane protein that is closely associated with the synthesis of heparan sulfate (HS), a key component of cartilage ([@b16-ol-0-0-7838]). Mutations in the *EXT* gene affect glycosyltransferase activities, resulting in an HS synthesis barrier. Nonsense mutations, frameshift mutations and splice site mutations account for 80% of mutations in patients with HMO.

In the present study, the clinical data of members from three generations of a single family with HMO were collected and statistically analyzed. Using two known genes of HMO, *EXT1* and *EXT2*, the genomic DNA of the family members was directly sequenced using a polymerase chain reaction (PCR), in order to identify the pathogenesis of the family with HMO and explore the potential underlying mechanism. The results of the present study may be useful for the clinical genetic counseling of similar diseases in the future.

Materials and methods
=====================

### Patients and clinical data

A three-generation HMO family, JX-JJ001 (Jiangxi, China) were the subject of the present study ([Fig. 1](#f1-ol-0-0-7838){ref-type="fig"}). Diagnostic criteria: X-ray examination revealed that the long bone metaphysis had at least two or more osteochondromas. According to the above criteria, it was confirmed that five patients (4 male, 1 female) in the family exhibited generation inheritance of HMO. All participants provided informed consent for specimen and information collection. Clinical data were obtained from pedigree patients by the questionnaire survey, which included family history, age of onset, age of diagnosis, evolution of the disease, history of surgery, the location of exogenous bone warts, limb deformities or limited joint activity, and other relevant clinical symptoms such as malignant transformation and mortality ([Fig. 1](#f1-ol-0-0-7838){ref-type="fig"} and [Table I](#tI-ol-0-0-7838){ref-type="table"}). The five patients within the family and three healthy individuals were involved in the present study. All five HMO patients in the family exhibited multiple exostosis, including in the femur, tibia, fibula and knee. All five patients had shorter than normal limbs, but did not exhibit serious limb deformity, with no symptoms of hip or knee valgus or limited mobility. None of the patients had serious complications, only feeling that the mass was protruding into the body surface or occasional pain (mean visual analogue scale score, 2.7 points); however, these symptoms did not limit the mobility of the knee. The average age of the HMO family was 37.4 years old. Prior to the present study, no patient had undergone surgical resection of osteochondroma. The mean height of the pedigree patients was 155.4 cm in man, much lower than that of the China National Sports General data (which was 169.9 cm in men from 35--39 years) released in 2010 by the National Physical Monitoring Bulletin ([@b17-ol-0-0-7838]).

In addition to members of the JX-JJ001 family, a further 300 volunteers (153 males and 147 females; 19--45 years old; median age 35 years old) who were healthy and were not related to the family participated in the study. The present study was approved by the Zhejiang Provincial People\'s Hospital Ethics Committee (Hangzhou, China), and all participants provided written informed consent.

### Molecular analysis

The peripheral blood from the pedigree patients and the non-patient members was drawn and added to the EDTA anticoagulant tube, Next, the DNA was extracted from the blood using the AxyPrep Nucleic Acid Purification kit (Axygen Scientific, Inc., Union City, CA, USA) in accordance with the manufacturer\'s protocol. Following this, a Nanodrop2000 spectrophotometer (Nanodrop Technologies; Thermo Fisher Scientific, Inc., Wilmington, DE, USA) was used to quantify DNA. Primer 5.0 (Premier Biosoft International, Palo Alto, CA, USA) was used to design primers and primer sequences ([Table II](#tII-ol-0-0-7838){ref-type="table"}) for all exons of *EXT1* and *EXT2* (including the 100 bp base of exon and intron junctions). PCR (KAPA2G Fast Multiplex Mix; Kapa Biosystems, Inc., Wilmington, MA, USA) was used for the expansion of genomic DNA, with thermocycling conditions as follows: 94°C for 5 min, followed by 94°C for 30 sec and 60°C for 30 sec, for 30 cycles each, followed by 72°C for 1 min, 72°C for 5 min and 12°C for 10 min. Amplified DNA product was subjected to Sanger sequencing analysis using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and an ABI 3730XL automatic sequencer (Applied Biosystems; Thermo Fisher Scientific, Inc.). Samples from the patients and healthy controls were bi-directionally sequenced and the sequencing results were analyzed using Sequencer Demo 3.0 (Gene Codes Corporation, Ann Arbor, MI, USA) and Mutation Surveyor Demo V4.0 software (SoftGenetics, LLC, State College, PA, USA), with National Centre for Biotechnology Information (*EXT1*, NM_000127.2; *EXT2*, NM_001178083.1; <https://www.ncbi.nlm.nih.gov/>) sequences used as reference genes.

### Computer simulation analysis

The present study used Mutation Taster software ([@b18-ol-0-0-7838]) to predict the pathogenicity of mutations.

### Evolutionary conservation and structural prediction

ClustalX 1.83 ([@b19-ol-0-0-7838]) to analyze the conservativeness of mutant amino acids by comparing the human wild-type *EXT2* gene protein sequence (NP_000118) and the *EXT2* gene sequence (sequence from [www.ensembl.org/](www.ensembl.org/)) of other species, including mackerel, fruit fly, mouse, *Xenopus laevis* and *Caenorhabditis elegans*.

Results
=======

### DNA sequencing identified a novel mutation to the EXT2 gene in all patients with HMO

The tissue structure ([Fig. 2](#f2-ol-0-0-7838){ref-type="fig"}) of patients with HMO was characterized by a cartilage cap that was covered by a fibrous perichondrium and merged into an underlying spongy bone. Each exon of the *EXT1* and *EXT2* genes was sequenced in 5 patients (I1, II2, II3 III1, and III2, as shown in [Fig. 1](#f1-ol-0-0-7838){ref-type="fig"}) and 3 normal members (I2, II1 and II4, as shown in [Fig. 1](#f1-ol-0-0-7838){ref-type="fig"}) of the HMO family JX-JJ001. Following the data filtering procedures, all of the HMO patients were found to have mutations in the *EXT2* gene. A novel nonsense mutation was identified on the *EXT2* gene in the five HMO patients: c.67C\>C/T (amino acid R23\*), ([Fig. 3](#f3-ol-0-0-7838){ref-type="fig"}), it is worth noting that this novel nonsense 23R\>X mutation occurred only in the five HMO patients and was not found in other family members. Therefore, we hypothesize that this novel *EXT2* mutation site may be a pathogenic mutation site. According to this finding, the DNA of 300 healthy volunteers who were not associated with the family members was sequenced, and it was found that none of the *EXT2* genes in the 300 healthy volunteers had a 23R\>X mutation. Thus, this novel nonsense mutation 23R\>X in the *EXT2* gene is leading to pathogenicity of the HMO family JX-JJ001.

### 23R\>X mutation had a notable effect on the function of the EXT2 gene

To understand the effect of 23R\>X on the function of the *EXT2* gene, further computer simulation analysis was performed. The protein encoded by the *EXT2* gene was composed of 728 amino acids and that it had two notable domains: The exostosin domain (between the 101 and 380 amino acids) and the glycosyltransferase domain (between the 466 and 711 amino acids) ([Fig. 3B](#f3-ol-0-0-7838){ref-type="fig"}). Amino acid 23 (Arg) was present before the exostosin and glycosyltransferase domains. Furthermore, evolutionary conservation analysis revealed that the amino acids were highly conservative in multiple species ([Fig. 4](#f4-ol-0-0-7838){ref-type="fig"}). This result indicates that this amino acid serves a notable role in the function of the *EXT2* gene and remains in the process of biological evolution. This nonsense mutation 23R\>X causes the *EXT2* transcription process to be terminated prematurely and produces a truncated EXT2 protein, lacking the C-terminal 705 amino acids ([Fig. 3B](#f3-ol-0-0-7838){ref-type="fig"}). Since the glycosyltransferase domain serves a notable role in HS biosynthesis, the mutation 23R\>X is likely to have a significant effect on the function of the *EXT2* gene, particularly affecting the biosynthesis of HS. The same result was also observed with the online prediction tool Mutation Taster, which revealed that using stop codon to replace 23 arginine affects the function of the EXT2 protein and leads to the occurrence of the disease (probability score, 6.0) ([Fig. 5](#f5-ol-0-0-7838){ref-type="fig"}).

Discussion
==========

Although HMO is observed in Europe and the United States at an incidence of 1:50,000--100,000, to the best of our knowledge its incidence in China is not known ([@b3-ol-0-0-7838],[@b4-ol-0-0-7838]). Clinical characteristics often vary among individuals: Patients typically have symmetrical bony protrusions with cartilage caps in long bone growth plates, as well as short, flat and/or irregular bones; certain patients have disproportionate limbs and short stature ([@b20-ol-0-0-7838]). The onset age for half of all patients is \<3 years old. During growth and development, exostoses grow gradually; the growth plates eventually disappear and exostoses stop growing until puberty ([@b20-ol-0-0-7838]). The clinical symptoms and complications of HMO are associated with the location and size of exostoses; these symptoms include pain, short stature, skeletal deformities, oppression around the blood vessels and nerves, spontaneous pneumothorax and changes in joint mobility ([@b4-ol-0-0-7838]). The most serious complication is malignant chondrosarcoma or osteosarcoma, and the malignant transformation rate is 0.5--5% ([@b12-ol-0-0-7838]).

Human HMO is associated with at least two genes: *EXT1* on 8q24.11-q24.13 and *EXT2* on 11p12-11 ([@b21-ol-0-0-7838],[@b22-ol-0-0-7838]). These two tumor suppressor genes are widely expressed; *EXT1* contains 11 exons and 10 introns and encodes 746 amino acids, whereas *EXT2* contains 15 exons and 15 introns, with exons 2--14 form an open reading frame encoding 728 amino acids. The two genes are highly similar at the amino acid level, particularly in the C-terminal region. According to Human Mutation Database statistics, 595 HMO-associated mutations have been detected to date, including 401 mutations in *EXT1* and 194 mutations in *EXT2*; these include missense/nonsense mutations, small insertion/deletion mutations, splice site changes and large deletions ([@b23-ol-0-0-7838]). Although, to the best of our knowledge, the precise functions of these two genes is unknown, the proteins are localized in the type II transmembrane glycoproteins of the endoplasmic reticulum, which is associated with the synthesis of HS proteoglycan (HSPG) ([@b17-ol-0-0-7838]).

HSPG is composed of a core protein and an attached glycosaminoglycan chain ([@b24-ol-0-0-7838]). The proteins encoded by *EXT1* and *EXT2* form a heterologous oligomer in the Golgi apparatus of the majority of human cells ([@b25-ol-0-0-7838]). The heterologous oligomer, a glycosyltransferase complex, is involved in the polymerization of HS chains ([@b26-ol-0-0-7838]). The oligomer can add glucuronic acid and *N*-acetylglucosamine residues to HS chains alternately, forming HSPGs ([@b27-ol-0-0-7838]). The activity of the glycosyltransferase complex formed by the EXT1/EXT2 oligomer is higher compared with that of EXT1 or EXT2 alone ([@b28-ol-0-0-7838],[@b29-ol-0-0-7838]). HS is widely expressed in cell membranes and the extracellular matrix serves a notable role in receptor ligand binding, signal transduction and other physiological processes ([@b30-ol-0-0-7838]). HS proteoglycans are essential in several signaling pathways, including those involving fibroblast growth factors (FGFs), vascular endothelial growth factor and transforming growth factor-β, and may affect the concentration gradient of various morphogens on the cell surface, including bone morphogenetic proteins and hedgehog ([@b31-ol-0-0-7838]). HS proteoglycans can bind hedgehog ligands to control the spread of the hedgehog ligand in the extracellular matrix ([@b32-ol-0-0-7838]).

Hedgehog is a secretory protein that hydrolyzes itself, and the hedgehog signaling pathway serves a notable role in the regulation of growth plate chondrocytes ([@b33-ol-0-0-7838]--[@b35-ol-0-0-7838]). Hypertrophic chondrocytes of the growth plate may secrete Indian hedgehog (Ihh) ([@b36-ol-0-0-7838],[@b37-ol-0-0-7838]). Ihh functions with parathyroid hormone-related protein (PTHrP) and regulates endochondral bone formation via a negative feedback loop ([@b38-ol-0-0-7838]). Ihh can induce periarticular hypertrophic chondrocytes to increase the secretion of PTHrP, which can suppress the proliferation of chondrocytes into hypertrophic chondrocytes ([@b18-ol-0-0-7838]). Ihh can also individually control chondrocyte differentiation and induce periosteal osteogenesis ([@b39-ol-0-0-7838]). In the regulation of endochondral bone growth via Ihh-PTHrP, multiple factors serve notable roles, including bone morphogenetic proteins (BMPs), which promote Ihh expression in cartilage cells ([@b40-ol-0-0-7838]).

Mutations in *EXT1* and *EXT2* can lead to the expression of truncated proteins that are associated with decreased activity of the glycosyltransferase complex ([@b17-ol-0-0-7838]). Synthesis of the HS chain is then reduced, which leads to the formation of incomplete HS proteoglycans ([@b26-ol-0-0-7838],[@b27-ol-0-0-7838]). The incomplete HS proteoglycans cause ligand-receptor binding disorders in a number of signaling pathways, including Ihh, BMPs, FGF, and Wnt, which affects the concentration gradient of ligands on the cell surface or in the extracellular matrix ([@b30-ol-0-0-7838],[@b31-ol-0-0-7838]). Disorders in the Ihh signaling pathway cause Ihh secretion and increase secretion of PTHrP by periarticular hypertrophic chondrocytes ([@b18-ol-0-0-7838]). This influences the proliferative potential of chondrocytes into hypertrophic chondrocytes and causes chondrocytes to undergo a long proliferative period, and ultimately HMO ([@b41-ol-0-0-7838]--[@b44-ol-0-0-7838]). Additionally, abnormal HS proteoglycans may change the morphology and differentiation potential of perichondrocytes, resulting in perichondrial cells that function as growth-plate-like cells and give rise to chondrocytes that clonally expand and develop into an exostosis, leading to HMO ([@b25-ol-0-0-7838]).

A lower disease burden is observed in individuals with *EXT2* mutations than in those with *EXT1* mutations ([@b15-ol-0-0-7838]). In a study examining 172 individuals from 78 families, Porter *et al* ([@b12-ol-0-0-7838]) verified a higher severe disease frequency in persons with mutations in *EXT1* than in those with *EXT2* mutations, as evidenced by shortened stature, skeletal deformities (shortened forearm or bowing and knee deformities), and function (decreased range of motion in the elbow, forearm and/or knee) ([@b13-ol-0-0-7838]). Individuals with *EXT2* mutations have fewer exostoses, a lower incidence of limb misalignment with longer limb segments and height, and less frequent pelvic and flat bone involvement than those with *EXT1* mutations ([@b45-ol-0-0-7838]).

The present study reveals a novel heterozygous nonsense mutation (c.67C\>T) in *EXT2*, using whole-exome sequencing. The mutation was validated by Sanger sequencing and its negative influence on the expression of EXT2 was examined via *in silico* analysis. The results of the current study provide information regarding the association between the *EXT* gene family and HMO. These findings may facilitate early diagnosis and prenatal genetic screening of HMO.
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![Pedigree of the Chinese family with hereditary multiple exostoses. The filled symbols represent affected individuals, and empty symbols indicate unaffected family members. The proband (III1; first member of the third generation of the family) is noted with an arrow. There is no consanguinity in this family. Squares indicate male patients, circles indicate female patients. HMO, hereditary multiple osteochondroma.](ol-15-04-4383-g00){#f1-ol-0-0-7838}

![Radiograph images of patients, III1 (A and B) and II2 (C and D). (A-D) Multiple osteochondromas are observed around the bilateral knee.](ol-15-04-4383-g01){#f2-ol-0-0-7838}

![DNA sequencing was used to identify a novel mutation in the *EXT2* gene. (A) The heterozygous nonsense mutation c.67C\>T (p.Arg23\*) was detected in the *EXT2* gene of HMO patients (under panel) but not in that of healthy controls (upper panel). (B) The mutation c.(67C\>T), located in exon 2, was predicted to introduce a premature stop codon at position 67, resulting in a truncation of 23 amino acids at the C-terminus of the EXT2 protein. *EXT2*, exostosin-2; HMO, hereditary multiple osteochondroma.](ol-15-04-4383-g02){#f3-ol-0-0-7838}

![Sequence alignment of *EXT2* orthologs. *EXT2*, exostosin-2.](ol-15-04-4383-g03){#f4-ol-0-0-7838}

![MutationTaster predicted that the substitution of R23 to the termination codon causes diseases. *EXT2*, exostosin-2; NMD, nonsense-mediated mRNA decay.](ol-15-04-4383-g04){#f5-ol-0-0-7838}

###### 

Clinical data for five hereditary multiple osteochondroma patients.

  Patient   Sex      Height, cm   Age of onset, years   Age at time of study, years   Localization
  --------- -------- ------------ --------------------- ----------------------------- ---------------------------------------
  1         Male     172.5        75                    75                            Femurs, tibia, fibula and knee joints
  2         Female   157.4        37                    45                            Femurs, tibia, fibula and knee joints
  3         Male     159.2        38                    42                            Femurs, tibia, fibula and knee joints
  4         Male     160.5          7                   15                            Femurs, tibia, fibula and knee joints
  5         Male     129.4          6                   10                            Femurs, tibia, fibula and knee joints

###### 

Primer sequences used to sequence the *EXT2* genes.

  Primers         Forward                          Reverse
  --------------- -------------------------------- --------------------------------
  *EXT2*-E1       5′-ATTGCCCTCCAGGAATGTTA-3′       5′-GCAGGAGTGGAAATCGGAG-3′
  *EXT2*-E2       5′-GGCGTGGTGGTCACAGTTAC-3′       5′-ACCAACTCAAGAGCAGAAGCA-3′
  *EXT2*-E3       5′-CTGTTGGGATTTCCAGGAGTTT-3′     5′-TGCCAGGACATAAGCCCTAACT-3′
  *EXT2*-E4       5′-TGATTCAAGGATAGAACGCAG-3′      5′-AAACAAAGGAGAGAACGGAGT-3′
  *EXT2*-E5       5′-GTGGAGGTGAAGACTGGTAAGG-3′     5′-CACAAGACACCAGACATCCAAG-3′
  *EXT2*-E6       5′-GGCGTCAACCCTTGTAGAAAC-3′      5′-CCTTGGTTTGTGAACTGCTCT-3′
  *EXT2*-E7       5′-GAAGGAGGTTTGGGATGTTGTT-3′     5′-AAGTAAACCCCACTCAGGCATT-3′
  *EXT2*-E8       5′-AAGTGTGCCTGGTTGGAGTG-3′       5′-ACTGCTGAAACCCTGCTGTG-3′
  *EXT2*-E9       5′-TAAAGGAATTAGCCTAACCTGGAG-3′   5′-CCCAAGTATAAAAAGCACACTCTC-3′
  *EXT2*-E10      5′-GTAAAAGCCACCAAGCCTGC-3′       5′-GTATGCCAGGGCTTGGAGTT-3′
  *EXT2*-E11      5′-CTTTGGATTTGATGAGAGCCG-3′      5′-CCCACACTCTTACGCACACCT-3′
  *EXT2*-E12      5′-TCTCCAGAATCCCATTATGACCT-3′    5′-ATGGTTATCTCGAAGTGACAGGA-3′
  *EXT2*-E13      5′-GCCTCCTTTTACCCTTCCTATT-3′     5′-GACCGCATCAATCATAGAACCT-3′
  *EXT2*-E14      5′-CTTGTGAGTTCTGCCGTTGG-3′       5′-GACCCTTCCAGCCATTACAAA-3′
  *EXT2*-E14-CX                                    5′-ATGGAGGTGACTATGGCTAC-3′
  *EXT2*-E15-1    5′-TTTGCTGTTATCTCTCAACCTCT-3′    5′-AGGAATTGGTGTTTAAGACACAG-3′
  *EXT2*-E15-2    5′-TACATCAATGAGTTCTTTCAGGGA-3′   5′-ACGCTGACTGGCAAAACAACTA-3′
  *EXT2*-E15-CX                                    5′-AACTGTGGCTAATCTTAATA-3′

*EXT2*-E1, exostosin-2 exon 1.
